Last reviewed · How we verify
SEP-225289 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SEP-225289 (SEP-225289) — Sumitomo Pharma America, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SEP-225289 TARGET | SEP-225289 | Sumitomo Pharma America, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SEP-225289 CI watch — RSS
- SEP-225289 CI watch — Atom
- SEP-225289 CI watch — JSON
- SEP-225289 alone — RSS
Cite this brief
Drug Landscape (2026). SEP-225289 — Competitive Intelligence Brief. https://druglandscape.com/ci/sep-225289. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab